文献速递淋巴瘤

BET蛋白蛋白水解靶向嵌合体(PROTAC)对套细胞淋巴瘤细胞具有强效致死活性

BET protein proteolysis targeting chimera (PROTAC) exerts potent lethal activity against mantle cell lymphoma cells.
PubMed 文献 · Leukemia · 2017-06-30

研究对比BET-PROTAC(ARV-825、ARV-771)与BET抑制剂在套细胞淋巴瘤(MCL)细胞中的活性。BET-PROTAC招募E3泛素连接酶降解BET蛋白,诱导更多凋亡(包括对伊布替尼耐药的细胞),并在免疫缺陷小鼠模型中较BET抑制剂OTX015更改善生存。ARV-771与伊布替尼、维奈克拉或帕博西尼联用协同诱导凋亡。

要点

  • BET-PROTAC降解BET蛋白,较BET抑制剂诱导更多MCL细胞凋亡,包括伊布替尼耐药细胞。
  • ARV-771在免疫缺陷小鼠MCL模型中较OTX015更抑制体内生长并改善生存。
  • ARV-771与伊布替尼、维奈克拉或帕博西尼联用协同诱导MCL细胞凋亡。

核心结论

  • BET-PROTAC较BET抑制剂表现出有前景且更优的临床前活性,需进一步体内评估其作为伊布替尼敏感或耐药MCL的治疗。

研究设计与样本

  • 研究对比BET-PROTAC(ARV-825、ARV-771,Arvinas公司)与BET抑制剂在MCL细胞及免疫缺陷小鼠移植模型中的活性。

主要发现

  • BET-PROTAC较BET抑制剂诱导更多MCL细胞凋亡,包括对伊布替尼耐药的细胞。
  • BET-PROTAC较BET抑制剂引起更多mRNA和蛋白表达扰动,耗竭c-Myc、CDK4、cyclin D1及NF-κB转录靶点Bcl-xL、XIAP和BTK,同时诱导HEXIM1、NOXA和CDKN1A/p21水平。
  • ARV-771较BET抑制剂OTX015更抑制免疫缺陷小鼠MCL移植瘤体内生长并诱导更大生存改善。
  • ARV-771与伊布替尼、BCL2拮抗剂维奈克拉或CDK4/6抑制剂帕博西尼联用协同诱导MCL细胞凋亡。

局限性

  • 原文结论指出需进一步体内评估BET-PROTAC作为伊布替尼敏感或耐药MCL的治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Bromodomain extraterminal protein (BETP) inhibitors transcriptionally repress oncoproteins and nuclear factor-κB (NF-κB) target genes that undermines the growth and survival of mantle cell lymphoma (MCL) cells. However, BET bromodomain inhibitor (BETi) treatment causes accumulation of BETPs, associated with reversible binding and incomplete inhibition of BRD4 that potentially compromises the activity of BETi in MCL cells. Unlike BETi, BET-PROTACs (proteolysis-targeting chimera) ARV-825 and ARV-771 (Arvinas, Inc.) recruit and utilize an E3-ubiquitin ligase to effectively degrade BETPs in MCL cells. BET-PROTACs induce more apoptosis than BETi of MCL cells, including those resistant to ibrutinib. BET-PROTAC treatment induced more perturbations in the mRNA and protein expressions than BETi, with depletion of c-Myc, CDK4, cyclin D1 and the NF-κB transcriptional targets Bcl-xL, XIAP and BTK, while inducing the levels of HEXIM1, NOXA and CDKN1A/p21. Treatment with ARV-771, which possesses superior pharmacological properties compared with ARV-825, inhibited the in vivo growth and induced greater survival improvement than the BETi OTX015 of immune-depleted mice engrafted with MCL cells. Cotreatment of ARV-771 with ibrutinib or the BCL2 antagonist venetoclax or CDK4/6 inhibitor palbociclib synergistically induced apoptosis of MCL cells. These studies highlight promising and superior preclinical activity of BET-PROTAC than BETi, requiring further in vivo evaluation of BET-PROTAC as a therapy for ibrutinib-sensitive or -resistant MCL.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Sun B, Fiskus W, Qian Y, et al. BET protein proteolysis targeting chimera (PROTAC) exerts potent lethal activity against mantle cell lymphoma cells. Leukemia. 2017. PMID: 28663582. doi:10.1038/leu.2017.207

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。